Two patients in Scotland get stem cell transplants to treat blindness

May 22, 2012 by Bob Yirka in Ophthalmology report

Two patients in Scotland get stem cell transplants to treat blindness

(Medical Xpress) -- Two people in Scotland have received stem cell transplants into their eyes in a clinical trial that is aimed at restoring vision in people that suffer some degree of blindness due to damage to the cornea. One of the patients has agreed to have their name released; Sylvia Paton, of Edinburgh. She suffers from a hereditary disease called aniridia which causes incomplete formation of the iris and leads to damage to the cornea. In Mrs. Paton’s case, the condition led to havening no iris at all in one eye and just ten percent vision, along with a heightened sensitivity to light. She received the transplant in February (performed by Dr. Ashish Agrawal) but neither she nor her team of doctors will know how effective the treatment has been for many more months.

The cornea is the clear coating that covers the outside of the eyeball. Current treatment for those that suffer irreversible damage to it either from disease or injury relies on cornea transplants from deceased donors. The new treatment called corneal epithelial stem cell transplantation uses stem cells grown by the Scottish National Blood Transfusion Service (SNBTS). In the procedure, dead material is removed from the cornea (along with a cataract in Mrs. Paton’s case) and the stem cells are placed onto the remaining edges of the existing healthy cells. From there, the stem cells slowly grow into a fully formed cornea, hence the long wait to find out how effective the treatment has been.

In Mrs. Paton’s case, her doctors can’t be sure how much improvement in vision she will have even if the cornea grows perfectly as it’s not known how well the rest of her eyes work.

The stem cell transplantation treatment has been developed by Scottish specialists over a period of several years with the culmination being the current clinical trial which involves a total of ten patients, eight of which have not yet had the procedure. In addition to the ten who will receive the transplants, another group of ten patients with similar conditions will receive traditional treatment to serve as a control group. The researchers expect it will take up to 12 months for patients to grow a new cornea from the stem cells, but if successful, the new treatment will likely revolutionize the treatment of blindness due to problems with the cornea, which is second only to cataracts as a cause of , with about 20 million people affected worldwide.

More information: Press release

© 2012 Phys.Org

4.6 /5 (8 votes)  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

El_Nose
May 22, 2012

Rank: not rated yet
http://abcnews.go...VR0XY9sk

http://www.webmd....s-vision

--best one --

http://blogs.disc...e-again/

This is old -- Italy has been doing stem cell treatments for cornea since mid nineties. This is making headlines in UK because on the the medical journals finally published a review on the Italian treatment last year.
Rank 4.6 /5 (8 votes)
Related Stories
Relevant PhysicsForums posts

More news stories

Glaucoma drug can cause droopy eyelids

Prostaglandin analogues (PGAs), drugs which lower intraocular pressure, are often the first line of treatment for people with glaucoma, but their use is not without risks. PGAs have long been associated with blurred vision, ...

Ophthalmology created May 21, 2013 | popularity not rated yet | comments 0

Eyes on the sun: Child sunshine exposure and eye development

(Medical Xpress)—Exposure to sunshine as a small child is crucial to the development of a healthy eye according to results of long-term myopia study conducted by University of Sydney researchers.

Ophthalmology created May 21, 2013 | popularity 5 / 5 (1) | comments 0

New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery

The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial ...

Ophthalmology created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast

Early screenings key to diagnosing glaucoma

New research is emphasizing the importance of regular screenings for glaucoma, a disease that deteriorates the optic nerve over time and is a leading cause of irreversible blindness worldwide. The onset of glaucoma is associated ...

Ophthalmology created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast

University partners with Sony to find cure for 'lazy eye'

The University of Nottingham and Nottingham University Hospitals NHS Trust, have been working with Sony Computer Entertainment Europe (SCEE) to develop special 3-D glasses and games to help treat children ...

Ophthalmology created May 08, 2013 | popularity not rated yet | comments 0


Slowing the aging process—only with antibiotics

Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.

Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.

Having both migraines, depression may mean smaller brain

(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.

Novel approach for influenza vaccination shows promise in early animal testing

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...

Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...